Literature DB >> 2428872

Two distinct but overlapping antibody binding sites in the pre-S(2) region of HBsAg localized within 11 continuous residues.

D R Milich, A McLachlan, F V Chisari, T Nakamura, G B Thornton.   

Abstract

The fine specificity of the humoral immune response to the pre-S(2) region of the hepatitis B surface antigen was studied. It was demonstrated that the murine antibody response to the pre-S(2) region is focused on residues 133 through 143, and two distinct but overlapping epitopes were identified within 11 continuous residues. One epitope, defined by p133-139, is group specific, and the other epitope, defined by p137-143, is influenced by a subtype-dependent amino acid substitution at residue 141. However, the influence of residue 141 was "covert" in that it was only detected when synthetic antigens of 19 amino acids or smaller were used as the solid-phase ligand. The minimum size of both epitopes (p133-139 and p137-143) was seven amino acids. The physical and chemical form of the immunogen (i.e., protein vs peptide; conjugated vs free peptide) influenced antibody fine specificity. In quantitative antibody inhibition studies it was demonstrated that antibodies with nonoverlapping as well as overlapping fine specificities were capable of mutual inhibition. Finally, human HBV-infected, patient sera were shown to possess anti-pre-S(2) region antibodies that recognized sequences in common with the murine antisera. These results have implications relevant to the design of synthetic and recombinant second generation HBV vaccines and diagnostic reagents.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2428872

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope.

Authors:  D R Milich; J L Hughes; A McLachlan; G B Thornton; A Moriarty
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

Review 2.  The humoral immune response in acute and chronic hepatitis B virus infection.

Authors:  D R Milich; M Sallberg; T Maruyama
Journal:  Springer Semin Immunopathol       Date:  1995

3.  Immunogenicity of a recombinant Pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster.

Authors:  B Bucher; P Francioli; B Geudelin; B Fritzell; D Lavanchy; P C Frei
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-03       Impact factor: 3.267

4.  Hybrid hepatitis B virus core-pre-S proteins synthesized in avirulent Salmonella typhimurium and Salmonella typhi for oral vaccination.

Authors:  F Schödel; S M Kelly; D L Peterson; D R Milich; R Curtiss
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

5.  The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.

Authors:  F Schödel; A M Moriarty; D L Peterson; J A Zheng; J L Hughes; H Will; D J Leturcq; J S McGee; D R Milich
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

6.  Autoantibody production in hepatitis B e antigen transgenic mice elicited with a self T-cell peptide and inhibited with nonself peptides.

Authors:  D R Milich; A McLachlan; A K Raney; R Houghten; G B Thornton; T Maruyama; J L Hughes; J E Jones
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

7.  Hepatitis B virus pre-S2 start codon mutations in Indonesian liver disease patients.

Authors:  Andi Utama; Marlinang Diarta Siburian; Ismail Fanany; Mariana Destila Bayu Intan; Rama Dhenni; Tri Shinta Kurniasih; Syafruddin A R Lelosutan; Wenny Astuti Achwan; Nasrul Zubir; Benyamin Lukito; Irawan Yusuf; Laurentius Adrianus Lesmana; Ali Sulaiman
Journal:  World J Gastroenterol       Date:  2012-10-14       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.